Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • HIV-infected patients should be assessed for typical CVD risk factors, hyperlipidemia, and diabetes at entry into care
    • Fasting lipid profile and screening for diabetes should be performed every 6-12 months in all patients, as well as with screening for dyslipidemia and diabetes before ART initiation, and 1-3 months after ART initiation or switches[Aberg 2014]
  • Frequent blood pressure monitoring is advised

Action required